Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Teva
Colorcon
Express Scripts
Medtronic
Novartis
Cerilliant
US Department of Justice
Baxter
Farmers Insurance

Generated: January 17, 2018

DrugPatentWatch Database Preview

Olopatadine hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for olopatadine hydrochloride and what is the scope of olopatadine hydrochloride patent protection?

Olopatadine hydrochloride
is the generic ingredient in five branded drugs marketed by Akorn Inc, Apotex Inc, Aurobindo Pharma Ltd, Barr Labs Inc, Cipla Ltd, Somerset Theraps Llc, Usv North America, Wockhardt Ltd, Zambon Spa, Novartis Pharms Corp, and Perrigo Israel, and is included in fifteen NDAs. There are six patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Olopatadine hydrochloride has fifty-five patent family members in twenty-four countries.

There are seventeen drug master file entries for olopatadine hydrochloride. Eighteen suppliers are listed for this compound. There are five tentative approvals for this compound.
Summary for olopatadine hydrochloride
Pharmacology for olopatadine hydrochloride
Medical Subject Heading (MeSH) Categories for olopatadine hydrochloride
Tentative approvals for OLOPATADINE HYDROCHLORIDE
Applicant Application No. Strength Dosage Form
➤ Subscribe➤ Subscribe0.2% BASESOLUTION; OPHTHALMIC
➤ Subscribe➤ Subscribe0.1%SOLUTION; OPHTHALMIC
➤ Subscribe➤ Subscribe0.1%SOLUTION/DROPS; OPHTHALMIC

US Patents and Regulatory Information for olopatadine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp PAZEO olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 206276-001 Jan 30, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Akorn Inc OLOPATADINE HYDROCHLORIDE olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 204532-001 Jan 10, 2017 AT RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novartis Pharms Corp PAZEO olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 206276-001 Jan 30, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis Pharms Corp PAZEO olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 206276-001 Jan 30, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Zambon Spa OLOPATADINE HYDROCHLORIDE olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 204706-001 Dec 7, 2015 AT RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Usv North America OLOPATADINE HYDROCHLORIDE olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 203152-001 Dec 7, 2015 AT RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novartis Pharms Corp PATADAY olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 021545-001 Dec 22, 2004 AT RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis Pharms Corp PATADAY olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 021545-001 Dec 22, 2004 AT RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis Pharms Corp PATANASE olopatadine hydrochloride SPRAY, METERED;NASAL 021861-001 Apr 15, 2008 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Barr Labs Inc OLOPATADINE HYDROCHLORIDE olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 090848-001 Jul 13, 2015 AT RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for olopatadine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp PATANOL olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 020688-001 Dec 18, 1996 ➤ Subscribe ➤ Subscribe
Novartis Pharms Corp PATADAY olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 021545-001 Dec 22, 2004 ➤ Subscribe ➤ Subscribe
Novartis Pharms Corp PATANOL olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 020688-001 Dec 18, 1996 ➤ Subscribe ➤ Subscribe
Novartis Pharms Corp PATADAY olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 021545-001 Dec 22, 2004 ➤ Subscribe ➤ Subscribe
Novartis Pharms Corp PATANOL olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 020688-001 Dec 18, 1996 ➤ Subscribe ➤ Subscribe
Novartis Pharms Corp PATANOL olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 020688-001 Dec 18, 1996 ➤ Subscribe ➤ Subscribe
Novartis Pharms Corp PATANASE olopatadine hydrochloride SPRAY, METERED;NASAL 021861-001 Apr 15, 2008 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for olopatadine hydrochloride

Supplementary Protection Certificates for olopatadine hydrochloride

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0040 France ➤ Subscribe PRODUCT NAME: OLOPATADINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/02/217/001 20020517
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Deloitte
Julphar
Cerilliant
US Army
Healthtrust
Harvard Business School
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot